Understanding How a Key Protein Helps Aggressive Blood Cancer Grow, Paving the Way for Targeted Therapies

Aggressive forms of acute myeloid leukemia (AML) remain challenging to treat, especially in patients with FLT3-ITD mutations. Researchers from Japan have identified SETD1B as a key epigenetic regulator that promotes leukemia cell growth by promoting MYC activation through H3K4me3 modification. Using laboratory models, they demonstrated that disrupting SETD1B significantly slows cancer cell proliferation. These findings offer promising new avenues for developing therapies against treatment-resistant AML.